Aug. 17 at 9:18 PM
$ITRM or:the latest science shows oral Orlynvah is the best medicine out there now for ESBL e Coli for this niche of patients- only thing more effective is hospital IV. So what’s the delta between two generics, two office visits & a lab culture vs just giving a patient like this Orlynvah, when she has a co morbidity/past ESBL E. coli uUTI? The cost of just using Orlynvah vs step therapy is probably a wash(depending on what Medicare actually ends up paying on Orlynvah- I’m using
$1000, not the
$1400 Fishman is hoping he’ll get from payors). But, Orlynvah is so effective at killing ESBL e coli, that insurers can run the numbers using AI & figure out it’s cheaper in the end to just use Orlynvah for this particular type of patient. That’s how Fishman can shoot for 1% of his projected 26 million resistant cases. PLUS: 72-76 % of the U.S. is overweight/ 44% is obese- obesity is a co morbidity- so in theory at least half of the 40 million uUTI cases last year had at least one co morbidity
